A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Lines Up 32.6 Billion Yen for 4 New Drug Discovery Support Projects
September 2, 2026
-
REGULATORY Astellas, Kyowa Kirin 1st Japan Pharmas to Cut US MFN Deals
September 1, 2026
-
BUSINESS Shionogi Pivoting to Function-Based Model in Global HR Revamp
September 1, 2026
-
BUSINESS Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure
August 31, 2026
-
BUSINESS Sumitomo Pharma Goes Global with Adjuvants, Targets 100 Billion Yen
August 31, 2026
-
REGULATORY Patient Group Flags Risks of Inconsistent Decisions on OTC-Like Drug Charges
August 28, 2026
-
REGULATORY Pharma Seeks Inflation-Liked Price Hikes, Freeze on Patent-Period Cuts for 2027 Revision
August 27, 2026
-
BUSINESS Belite Bio Eyes Japan Filing for Stargardt Drug within 3 Months
August 26, 2026
-
REGULATORY Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
-
COMMENTARY Beyond Dupixent: Next Wave of COPD Biologics Takes Shape
August 25, 2026
-
BUSINESS MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
-
BUSINESS Sawai’s Solo Tenelia Copy Raises Patent Questions Ahead of December Listing
August 21, 2026
-
BUSINESS DT-Axis Charts Path to 2nd-Stage DTx Approval with Depression App
August 21, 2026
-
BUSINESS Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
August 20, 2026
-
REGULATORY Japan Panel to Discuss Approval of 6 NMEs, Leqembi SC on Aug. 26
August 20, 2026
-
REGULATORY DPP Lawmaker Calls for Inflation Relief in 2027 Off-Year Drug Price Revision
August 19, 2026
-
REGULATORY CEA Review Group Wraps Up Technical Debate, Urges More Company Access
August 19, 2026
-
BUSINESS Keytruda Keeps Top Spot in Japan in April-June as Mounjaro Zooms: IQVIA
August 19, 2026
-
REGULATORY Japan Panel to Weigh Keytruda SC, J&J Psoriasis Pill among 6 NMEs on Aug. 24
August 18, 2026
-
REGULATORY Japan Calls for APOE Testing before Leqembi, Kisunla Treatment
August 18, 2026
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…